Literature DB >> 20131041

Thinking on how to construct the system of Chinese medicine efficacy evaluation for coronary heart disease angina pectoris.

Jie Wang1, Qing-yong He.   

Abstract

The existing efficacy evaluation for coronary heart disease (CHD) angina pectoris does not demonstrate the characteristics and advantages of Chinese medicine (CM), so a new system of efficacy evaluation which can scientifically and systematically reflect the specific features of CM needs to be urgently set up. Based on wide references of efficacy evaluations of CHD angina pectoris from our country and abroad, and considering the general acceptance by academic circles and demonstration of the characteristics of CM, this paper tries to set up a new index system of efficacy evaluation, combining both disease and syndrome differentiation for CHD angina pectoris. This paper also offers some explorations based on the results of clinical trials. The system is composed of six aspects, including efficacy evaluation of "disease", syndrome factors and main endpoints (the incidence of important clinical events), as well as patient reported outcomes, safety evaluation and medical economics.

Entities:  

Mesh:

Year:  2010        PMID: 20131041     DOI: 10.1007/s11655-010-0075-2

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  4 in total

Review 1.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

2.  The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization.

Authors: 
Journal:  Soc Sci Med       Date:  1995-11       Impact factor: 4.634

3.  [Evaluation on effects of disassembled formulas of Xuefu Zhuyu Decoction for treatment of angina pectoris using Seattle Angina Questionnaire].

Authors:  Lu Jing; Jie Wang; Ting Wang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2007-01

4.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance.

Authors: 
Journal:  Health Qual Life Outcomes       Date:  2006-10-11       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.